Drug Profile
S 3304
Latest Information Update: 15 May 2018
Price :
$50
*
At a glance
- Originator Shionogi
- Class Antineoplastics
- Mechanism of Action Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Non-small cell lung cancer
Most Recent Events
- 23 Feb 2005 Discontinued - Phase-I for Cancer in Europe (PO)
- 23 Feb 2005 Discontinued - Phase-I/II for Cancer in USA (PO)
- 03 Sep 2003 This compound is still in active development